Novel benzimidazolium bromides salts having (4-methoxyphenyl)ethyl, (phthalimide-2-yl)methyl, 4-nitro- benzyl, 2-phenylethyl, penthyl, or allyl groups were synthesized and their characterizations were conducted by $^{1}$H and $^{13}$C NMR and IR spectroscopic methods, and microanalysis. In vitro antitumor activities of the novel benzimidazole compounds (1-7) were determined by using ovarian (A2780) and prostate (PC-3) cancer cell lines. Antitumor properties of all compounds were determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. A time-dependent cell viability assay for the tested benzimidazole compounds was performed and the IC$_{50}$ values of the compounds were calculated after treatment for 24 and 48 h. Our results indicate that the tested benzimidazole compounds show antitumor activity against A2780 and PC-3 cell lines (P $